C-Rad AB (publ) (CRAD-B) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.205x

Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.10 Million ≈ $7.65 Million USD) by net assets (Skr347.20 Million ≈ $37.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRAD-B market cap overview for the company's overall valuation and market capitalisation.

C-Rad AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how C-Rad AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

C-Rad AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of C-Rad AB (publ) ranked by their cash flow conversion efficiency. Explore C-Rad AB (publ) earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Tempore Properties SOCIMI SAU
MC:YTEM
0.013x
Khonburi Sugar Public Company Limited
BK:KBS
0.252x
China Automotive Systems Inc
F:RYV
0.075x
Aspen Insurance Holdings Ltd
NYSE:AHL
0.087x
Silver Pegasus Acquisition Corp.
NASDAQ:SPEG
-0.001x
Inhibikase Therapeutics Inc
NASDAQ:IKT
-0.145x
Iris Clothings Limited
NSE:IRISDOREME
-0.103x
Lam Soon (Thailand) Public Company Limited
BK:LST
-0.011x

Annual Cash Flow Conversion Efficiency for C-Rad AB (publ) (2008–2025)

The table below shows the annual cash flow conversion efficiency of C-Rad AB (publ) from 2008 to 2025. View CRAD-B stock price and chart for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr347.20 Million
≈ $37.36 Million
Skr71.10 Million
≈ $7.65 Million
0.205x +121.28%
2024-12-31 Skr324.99 Million
≈ $34.97 Million
Skr30.08 Million
≈ $3.24 Million
0.093x -21.94%
2023-12-31 Skr281.60 Million
≈ $30.30 Million
Skr33.38 Million
≈ $3.59 Million
0.119x +196.73%
2022-12-31 Skr242.54 Million
≈ $26.10 Million
Skr9.69 Million
≈ $1.04 Million
0.040x -49.18%
2021-12-31 Skr231.09 Million
≈ $24.87 Million
Skr18.17 Million
≈ $1.96 Million
0.079x -14.85%
2020-12-31 Skr199.79 Million
≈ $21.50 Million
Skr18.45 Million
≈ $1.99 Million
0.092x -51.38%
2019-12-31 Skr83.33 Million
≈ $8.97 Million
Skr15.83 Million
≈ $1.70 Million
0.190x +285.14%
2018-12-31 Skr93.64 Million
≈ $10.08 Million
Skr-9.61 Million
≈ $-1.03 Million
-0.103x -82.21%
2017-12-31 Skr71.41 Million
≈ $7.68 Million
Skr-4.02 Million
≈ $-432.62K
-0.056x +91.09%
2016-12-31 Skr70.60 Million
≈ $7.60 Million
Skr-44.62 Million
≈ $-4.80 Million
-0.632x -10.29%
2015-12-31 Skr40.05 Million
≈ $4.31 Million
Skr-22.95 Million
≈ $-2.47 Million
-0.573x -38.13%
2014-12-31 Skr40.04 Million
≈ $4.31 Million
Skr-16.61 Million
≈ $-1.79 Million
-0.415x +30.97%
2013-12-31 Skr38.03 Million
≈ $4.09 Million
Skr-22.86 Million
≈ $-2.46 Million
-0.601x +25.17%
2012-12-31 Skr16.26 Million
≈ $1.75 Million
Skr-13.06 Million
≈ $-1.41 Million
-0.803x -41.62%
2011-12-31 Skr36.02 Million
≈ $3.88 Million
Skr-20.43 Million
≈ $-2.20 Million
-0.567x -444.26%
2010-12-31 Skr48.12 Million
≈ $5.18 Million
Skr-5.01 Million
≈ $-539.60K
-0.104x +64.39%
2009-12-31 Skr29.82 Million
≈ $3.21 Million
Skr-8.73 Million
≈ $-939.06K
-0.293x -2.01%
2008-12-31 Skr35.05 Million
≈ $3.77 Million
Skr-10.06 Million
≈ $-1.08 Million
-0.287x --

About C-Rad AB (publ)

ST:CRAD-B Sweden Medical Devices
Market Cap
$119.27 Million
Skr1.11 Billion SEK
Market Cap Rank
#18621 Global
#320 in Sweden
Share Price
Skr34.50
Change (1 day)
-2.27%
52-Week Range
Skr24.90 - Skr38.80
All Time High
Skr66.70
About

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more